Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSV | O60911 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21442758 | 1.00 | CA1 (0.39) | CA1CA9HTR2BMAPTCTSL | |
| SCHEMBL10308830 | 0.83 | HTR2B (0.38) | CA1CA9HTR2BMAPTGRM2 | |
| SCHEMBL13749119 | 0.82 | CA1 (0.34) | CA1CA9CTSLCTSBCTSS | |
| SCHEMBL20181327 | 0.78 | HTR2B (0.36) | HTR2BMAPTCTSLCTSBCTSS | |
| SCHEMBL20181452 | 0.78 | HTR2B (0.36) | HTR2BMAPTCTSLCTSBCTSS | |
| SCHEMBL22626006 | 0.76 | HTR2B (0.35) | HTR2BMAPTCTSLCTSBCTSS | |
| SCHEMBL20649458 | 0.74 | — | — | |
| SCHEMBL6551798 | 0.72 | GRM2 (0.34) | CA1CA9MAPTGRM2SMN1; SMN2 | |
| SCHEMBL13950161 | 0.71 | HTR2B (0.45) | HTR2BCTSLCTSBCTSSCTSV | |
| SCHEMBL13950164 | 0.70 | HTR6 (0.42) | HTR2BMAPTGRM2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310777-B1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | CA1 1231/4885CA9 897/4885HTR2B 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.